The Hematologist

banner image

Successes in Gene Therapy: 2017

Dr. Hoggatt covers successes in gene therapy achieved during 2017 and expresses excitement in what's to come for the field. 

Read more
banner image

Old Dog, New Tricks

Dr. Jacobson looks at trials that show benefits of antibody therapy against CD20 in new contexts in MCL and FL 20 years after initial FDA approval of rituximab.

Read more
Current Issue Static Feature

Current Issue

January/February 2018
Volume 15, Issue 1

Read current issue

President's Column

Presidents Column - Kenneth AndersonHead of Hematology Section and Director of Comprehensive Thalassemia Program, A. Watson and Sarah Armour Endowed Chair for Childhood Cancer and Blood Disorders, Ann and Robert H. Lurie Children's Hospital; Associate Director of Equity and Minority Health, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
Hematology's "Red Carpet" for Innovation
January 24, 2018

In her inaugural President's Column, Dr. Alexis Thompson ushers in 2018 with a discussion of annual meeting media highlights.

View all president's column articles

  • Update on Tax Reform
    December 20, 2017

    On December 20, the House of Representatives and the Senate voted to approve H.R. 1, tax reform legislation. Select members of each chamber came together to resolve disagreements between the two versions passed by the House and Senate.

  • 2017 Action of the Affordable Care Act
    December 05, 2017

    Congress spent much of 2017 focused on the repeal and replace of the Affordable Care Act (ACA). Included is a summary of Congress and the Administration’s actions on repeal and replace of the ACA that occurred in 2017.

  • 2017 ASH Advocacy Activities
    November 29, 2017

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2017.

  • 2017 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait
    November 29, 2017

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2017.

View all Policy News